BRAF V600E

BRAF V600E
Name	BRAF V600E
Organism	Homo sapiens
Location	7q34
Type	Point mutation
Effect	Constitutive kinase activation

BRAF V600E BRAF V600E is a somatic point mutation in the BRAF proto-oncogene resulting in a valine-to-glutamic acid substitution at codon 600 that produces constitutive activation of the BRAF kinase. The mutation was first characterized in large-scale cancer genomics efforts and is notable for its prevalence in multiple malignancies and its role as a predictive biomarker for targeted therapies. It has been central to translational research linking molecular oncology cohorts, precision medicine consortia, and regulatory approvals for targeted inhibitors.

Molecular biology and mutation characteristics

The V600E substitution lies within the activation segment of the BRAF kinase domain encoded on chromosome 7 and was identified through tumor sequencing projects led by investigators associated with institutions such as Wellcome Sanger Institute, The Broad Institute, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, and Johns Hopkins University. Structural studies from laboratories at Harvard University and Stanford University demonstrated that the glutamic acid at position 600 mimics phosphorylation, stabilizing the active conformation observed in crystal structures deposited by groups linked to Protein Data Bank contributors. Population genetics and epidemiology reports from centers including Centers for Disease Control and Prevention and World Health Organization catalog variant frequency across cohorts assembled by consortia like The Cancer Genome Atlas and Catalogue Of Somatic Mutations In Cancer. Functional assays developed in collaboration with teams at University of Cambridge and University of Oxford mapped altered ATP affinity and downstream RAF-MEK-ERK signaling kinetics compared with wild-type BRAF.

Pathogenesis and cellular effects

Mechanistic work by laboratories at National Institutes of Health and Massachusetts Institute of Technology showed that V600E drives constitutive activation of the RAF-MEK-ERK pathway, promoting proliferation signals characterized in models used by groups at Cold Spring Harbor Laboratory and Fred Hutchinson Cancer Research Center. Studies connecting oncogenic signaling to cellular phenotypes used cell lines and xenograft models developed at University of California, San Francisco and Yale University to demonstrate effects on cell cycle regulators previously studied by researchers at Salk Institute and Karolinska Institute. Cross-talk with pathways investigated at Imperial College London and Rudolf Magnus Institute revealed impacts on apoptosis, senescence, and metabolic reprogramming that mirror findings from translational programs at Mayo Clinic and Cleveland Clinic.

Clinical significance and associated cancers

BRAF V600E is a major oncogenic driver in cancers profiled by consortia such as International Agency for Research on Cancer and appears at high frequency in tumor types characterized at centers like Memorial Sloan Kettering Cancer Center and Royal Marsden Hospital. It is prevalent in cutaneous melanoma cohorts curated by groups at American Association for Cancer Research and appears in subsets of colorectal cancer studied by teams at MD Anderson Cancer Center and Vanderbilt University Medical Center. The mutation is also important in papillary thyroid carcinoma registries coordinated by Beth Israel Deaconess Medical Center and in glioma classifications published by panels including experts from World Health Organization tumor classification working groups. Case series from institutions such as St. Jude Children’s Research Hospital and Children’s Hospital of Philadelphia have documented occurrences in pediatric histologies, while population studies from University of Toronto and University of Melbourne reported geographic and demographic variation.

Diagnostic detection methods

Diagnostic strategies developed by clinical laboratories affiliated with College of American Pathologists and European Society for Medical Oncology include immunohistochemistry using mutation-specific antibodies validated by centers like Roche and Dako, allele-specific PCR assays established in molecular diagnostics groups at Mayo Clinic and Quest Diagnostics, and next-generation sequencing panels deployed by facilities at Foundation Medicine and Illumina. Digital droplet PCR protocols refined by researchers at University of Pennsylvania and liquid biopsy approaches advanced by teams at Guardant Health enable circulating tumor DNA detection, complementing in situ hybridization and Sanger sequencing workflows standardized in guidelines from American Society of Clinical Oncology and National Comprehensive Cancer Network.

Therapeutic targeting and drug resistance

Targeted inhibition strategies emerged following clinical trials sponsored by organizations including National Cancer Institute, European Medicines Agency, and pharmaceutical companies such as Roche, Novartis, and GlaxoSmithKline. First-generation BRAF inhibitors evaluated at trial sites like University of California, Los Angeles and Memorial Sloan Kettering Cancer Center produced responses in melanoma cohorts, while combination regimens pairing MEK inhibitors developed by teams at Novartis and AstraZeneca addressed adaptive resistance characterized by research groups at Cold Spring Harbor Laboratory and Dana-Farber Cancer Institute. Resistance mechanisms explored by investigators at Fred Hutchinson Cancer Research Center, Stanford University, and National Institutes of Health include MAPK pathway reactivation, receptor tyrosine kinase upregulation, and MAP2K1/NRAS alterations; these findings informed next-generation inhibitors, combination immunotherapy strategies trialed at MD Anderson Cancer Center and sequencing approaches incorporated into protocols at Johns Hopkins University.

Prognosis and clinical outcomes

Prognostic implications have been defined in cohort studies reported by centers such as Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center, and Mayo Clinic, with context-dependent effects noted across tumor types in analyses published by editorial boards of The Lancet Oncology and Journal of Clinical Oncology. In melanoma, targeted therapy trials coordinated by groups at European Organisation for Research and Treatment of Cancer and Intergroup showed improved response rates but distinct durability compared to immunotherapy outcomes reported from University of California, San Francisco and Dana-Farber Cancer Institute. In colorectal and thyroid cancers, prognostic impact was refined through population studies from SEER Program and guideline committees at National Comprehensive Cancer Network, informing personalized management pathways adopted by oncology centers worldwide.

Category:Oncogenic mutations